The progestin-only contraceptive Depo-Provera 150mg delivered intramuscularly (150-IM), the most widely used injectable contraceptive worldwide, has been associated with increased HIV acquisition in many observational studies. The absence of causal evidence from randomized clinical trials has resulted in uncertainty about whether the observed association is due to methodological limitations or a real biological effect. Due to this uncertainty, and the risks associated with unplanned pregnancies, the World Health Organization advises that women at high risk of HIV can continue to use progestin injectables with counseling. Data on the effects of other long-acting contraceptives on HIV acquisition, such as implants and intrauterine devices (IUDs) are even more scarce; and there are no data on Sayana Press (DMPA-SQ 104mg, hereafter 104-SQ) and other lower dose DMPA formulations in development. This study will leverage three ongoing randomized trials to conduct timely, innovative, and cost efficient research to evaluate the impact of multiple contraceptives ? including 150-IM, the levonorgestrel (LNG) implant, the copper IUD, 104- SQ, and novel low dose DMPA formulations - on the female genital tract (FGT) microbial and immune environment.
The aims of this research are to: 1) analyze the vaginal microbiome of women by 16S rRNA gene survey and metagenomic sequencing for high-resolution analysis of bacteria, viruses, fungi, and parasites before and after initiation of 150-IM, 104-SQ, LNG implant or Cu-IUD; 2) evaluate levels of vaginal cytokines and antimicrobial proteins before and after initiation of 150-IM, 104-SQ, LNG implant or Cu-IUD; 3) evaluate changes in the frequency and activation of CCR5+, CCR6+CCR10- (Th17-like) and ?4?7 CD4+ T cells in the cervix among women using 150-IM, 104-SQ, LNG implant or Cu-IUD; 4) evaluate changes in the vaginal microbiome, cytokines and antimicrobial proteins with use of lower MPA doses (45, 75 and 105mg) compared to 150-IM, and the effect of systemic and genital endogenous and exogenous hormone levels on these outcomes; and 5) conduct a discovery metaproteomics analysis to evaluate alterations in vaginal human and microbial proteins following initiation of 150-IM, 104-SQ, LNG implant or Cu-IUD. This research will clarify the complex associations between contraceptive exposure, endogenous and exogenous hormones and the FGT microbiome, markers of immunity and inflammation, recruitment of HIV target cells and activation of those cells and markers of epithelial barrier repair. These data will inform contraceptive use and policy as well as provide targets and safety endpoints for the development of future contraceptives. Moreover, these data will provide the first evidence of FGT microbiome and immune changes that occur following initiation of other MPA based contraceptives, including 104-SQ and novel low dose MPA formulations which will be critically needed if the ECHO trial identifies increased acquisition of HIV among 150-IM users.

Public Health Relevance

A more complete mechanistic understanding of how different contraceptives modify the female genital tract (FGT) microbiome and immune response in ways that may alter HIV susceptibility is key to clarifying the conflicting results of epidemiologic studies of the impact of contraceptives on HIV acquisition, and to providing guidance for expansion and delivery of other long-acting contraceptives and progestin injectables, for which there are limited to no data, respectively, on risk of HIV acquisition. This study will leverage three randomized studies to conduct timely, innovative, and cost-efficient research to evaluate the impact of multiple contraceptives ? including Depo Provera, the levonorgestrel implant, the copper intrauterine device, Sayana Press (DMPA-SQ 104mg) and other novel low dose DMPA (45mg, 75mg, 105mg) formulations - on the FGT tract microbial and immune environment. These data will inform contraceptive use and policy, provide targets and safety endpoints for the development of future contraceptives, and provide the first evidence of FGT microbiome and immune changes that occur following initiation of DMPA-SQ 104mg and novel low dose MPA formulations.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
1R01HD096937-01
Application #
9618335
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Kaufman, Steven
Project Start
2018-09-18
Project End
2023-05-31
Budget Start
2018-09-18
Budget End
2019-05-31
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Family Health International
Department
Type
DUNS #
067180786
City
Durham
State
NC
Country
United States
Zip Code
27701